Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B funding round, raising RMB 1 billion (approximately USD 140 million). The round was jointly led by CS Capital and IDG Capital, with additional contributions from YanChuang Group, Cathay Capital, and existing investor Bain Capital.
The funds will be allocated to enhance clinical studies, explore application scenarios for the combination of bozitinib and andatinib, and facilitate simultaneous regulatory filings in the United States and China. Other priorities include compound screening, assessing draggability, and developing drug marketing and commercialization strategies.
Bozitinib, a small molecule MET inhibitor, was recently approved in China for treating locally advanced or metastatic non-small cell lung cancer with a mesenchymal epithelial transition factor (MET) exon 14 mutation. Its second indication filing has also been accepted for review by the National Medical Products Administration (NMPA) with priority review status.- Flcube.com
